TP53 and cancer: Notably, we previously demonstrated that mut-p53 protein accumulation drives down the expression of SLC7A11 through the inhibition of the transcription factor NRF2 (nuclear factor erythroid 2-related factor 2, encoded by NFE2L2), providing an explanation for the selectivity of eprenetapopt against mut-p53 cancer cells under some conditions (8).